Study on the efficacy and safety of Xuezhikang capsule combination with epalrestaton in treating diabetic peripheral neuropathy patients

This study retrospectively analyzes the clinical effect of Xuezhikang capsule combined with epalrestat on type 2 diabetic peripheral neuropathy. A total of 140 patients with type 2 diabetes combined with DPN were selected as the participants, which were divided into treatment group and control group, 70 cases respectively, according to different treatment schemes. The control group of patients received treatment with iprastam (50-mg/dose, 3 times/day) on the basis of controlling blood sugar, while the treatment group of patients received oral administration of Xuezhikang capsules (0.6-g/dose, 2 times/day) to regulate blood lipids on the basis of the control group's treatment plan, all treated for 12 weeks. Observe and compare the levels of laboratory indicators, Toronto Clinical Scoring System scores, and nerve conduction velocity before and after treatment between 2 groups of patients. After treatment, the levels of triglycerides, low-density lipoprotein, C-reactive protein, and tumor necrosis factor in the treatment group were measured. The level was lower than before treatment and the control group, while the level of high-density lipoprotein was higher than before treatment and the control group, with a statistically significant difference (P < .05); after treatment, the Toronto Clinical Scoring System scores of both groups were lower than before treatment, and the treatment group was lower than the control group, with a statistically significant difference; after treatment, the motor conduction velocity of the median nerve and common peroneal nerve, as well as the sensory conduction velocity of the sural nerve, median nerve, and common peroneal nerve in both groups were higher than before treatment, and the treatment group was higher than the control group, with statistical significance (P < .05); logistic regression analysis showed that high HbA1c, high triglycerides, high C-reactive protein, low high-density lipoprotein, and course of disease were risk factors for diabetes peripheral neuropathy (P < .05). Xuezhikang capsule can improve the blood lipid level and inflammatory factors in patients with type 2 diabetes, and the effect of Xuezhikang capsules combined with Epastatin on improving the conduction velocity, clinical score, and clinical symptoms of peripheral neuropathy.